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Abstract 1 
 2 
The impact of flavonoids on fatigue has not been investigated in Relapsing and Remitting Multiple 3 
Sclerosis (RRMS).  4 
 5 
Objective: To determine the feasibility and estimate the potential effect of flavonoid-rich cocoa on 6 
fatigue and fatigability in RRMS.   7 
 8 
Methods: A randomised double-blind placebo-controlled feasibility study in people recently 9 
diagnosed with RRMS and fatigue, throughout the Thames Valley (ISRCTN: 69897291). During a six 10 
week intervention participants consumed a high or low flavonoid cocoa beverage daily. Fatigue and 11 
fatigability were measured at three visits (weeks 0, 3 and 6). Feasibility and fidelity were assessed 12 
through recruitment and retention, adherence and a process evaluation.  13 
 14 
Results: 40 pwMS (10 men, 30 women, age 44 ± 10 yrs) were randomised and allocated to high 15 
(n=19) or low (n=21) flavonoid groups and included in analysis. Missing data was <20% and 16 
adherence to intervention of allocated individuals was >75%. There was a small effect on fatigue 17 
(Neuro-QoL: effect size {ES} 0.04; confidence interval {CI} -0.40-0.48) and a moderate effect on 18 
fatigability (six-minute walk test: ES 0.45; CI -0.18 - 1.07). There were seven adverse events (four 19 
control, three intervention), only one of which was possibly related and it was resolved.   20 
 21 
Conclusion: A flavonoid beverage demonstrates the potential to improve fatigue and fatigability in 22 
RRMS.   23 
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Introduction 24 
Ninety percent of people with Multiple Sclerosis (pwMS) experience fatigue [1].  Fatigue and 25 
fatigability are difficult to treat and greatly affect health related quality of life in pwMS [2]. 26 
Fatigability is a term derived from the broader definition of fatigue which refers to an inability to 27 
maintain both physical and cognitive performance [3]. The aetiology of fatigue in MS is complex 28 
including possible neural, inflammatory, metabolic and psychological mechanisms [2] [4]. Whilst a 29 
number of behavioural and drug approaches for fatigue management have been explored, to date the 30 
strongest evidence of success in reducing MS related fatigue is from exercise interventions [5] [6]. 31 
However success is limited and other approaches or combination therapies need to be investigated [7].  32 
Dark chocolate containing 70-85% cocoa solids is well known for its high antioxidant and 33 
flavonoid content.  Over a four week period, dark chocolate consumption has been shown to improve 34 
subjective fatigue in those with Chronic Fatigue Syndrome (CFS) [8] [9], and results from a small 35 
randomised controlled pilot study using a short-term cocoa intervention suggested an increase in sleep 36 
quality and reduction in fatigue [10]. A simple dietary supplement could be implemented alongside 37 
other behavioural interventions early after diagnosis as an adjunctive therapeutic approach to support 38 
pwMS to manage fatigue. There is currently limited evidence-based guidance to inform tailored 39 
dietary advice for symptom management in pwMS. Most diet based studies to date have looked at the 40 
risk of development or relapses in MS [11] [12]. However, modifiable lifestyle factors strongly 41 
correlate to clinically significant fatigue and remain a target for therapeutic trials [13]. To date there 42 
has been limited research assessing the effect of dietary interventions in pwMS [14], but they have 43 
identified good adherence to dietary interventions.  44 
We propose that a flavonoid approach for managing MS related fatigue may be moderately 45 
effective, inexpensive, and safe [15] and that it may be exerting its effects by reducing inflammation 46 
and oxidative stress. The aim of the current trial was to evaluate the feasibility and estimate potential 47 
effect to inform a follow-on substantive trial. The following key objectives were assessed: 1) The 48 
acceptance of the study design and diet intervention by participants; 2) Monitoring recruitment rate 49 
and the process of randomisation, adherence to the protocol and loss to follow up; 3) Efficiency of 50 
data collection methods; 4) The estimate of effect size for fatigue, fatigability and other measures.  51 
 52 
  53 
4 
 
Methods 54 
This was a parallel, randomised, double-blind placebo-controlled trial to assess feasibility and 55 
efficacy (Trial registration ISRCTN:  69897291; Ethical approval National Research Ethics Service 56 
{Solihull West Midlands} reference: 199515).  Oxford Brookes University acted as sponsor and the 57 
study was conducted in accordance with the Declaration of Helsinki. 58 
 59 
Recruitment  60 
Recruitment was through neurology clinics in the Thames Valley, UK. In addition, local MS Society 61 
branches were made aware of the trial and given contact details, and an advertisement for the study 62 
along with the participant information sheet (PIS) was made available on the MS Society website.   63 
Individuals were able to self-refer to the study by contacting the researchers. 64 
 65 
Setting 66 
The intervention took place in the home of each participant. All testing took place at Oxford Brookes 67 
University (OBU), Oxford, UK except for optional home visits at week 3. Assessments took place 68 
between 7.30 and 10 am and the intervention lasted a total of 6 weeks with three testing visits 69 
(baseline, week 3 and 6).  70 
 71 
Randomisation and allocation 72 
After recruitment, participants were allocated the next available study number by the blinded assessor. 73 
The study number related to a computer-generated randomisation list held by the principle 74 
investigator and randomised individuals (1:1) into the intervention or the control group. The 75 
randomisation list used minimisation to balance groups for gender and if individuals were on disease 76 
modifying treatments (DMTs) at baseline. The list provided a three digit code that related to a code on 77 
identical pre-package sachets (made up by a co-investigator) containing either intervention or control 78 
cocoa. The sachets were then dispensed to the participant. The intervention began three days after 79 
baseline. Group allocation was concealed throughout the study and analysis. 80 
 81 
Eligibility  82 
Eligibility criteria were: adults aged ≥18 years with a <10 year clinical diagnosis of RRMS, either 83 
treatment naïve or taking first line DMTs (supplementary file 1), no relapse or sudden change in MS 84 
symptoms within the previous three months, no contraindications to providing a blood sample or 85 
tolerating the cocoa drink, fatigue greater than 4 out of  7 on the Fatigue Severity Scale (FSS) [16], 86 
had no other conditions that may be associated with fatigue (e.g. anaemia), not on medication for the 87 
treatment of depression, an Expanded Disability Status Scale (EDSS ) score of < 4.5 [17], sufficient 88 
mental capacity to consent, able to walk with or without a walker for at least 16 meters, no condition 89 
affecting the central nervous system other than MS (migraine and headache were allowed), not 90 
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pregnant or lactating and no objection to the researchers contacting their general practitioner (family 91 
doctor) and neurologist. 92 
 93 
Intervention 94 
Participants were provided with cocoa by the lead researcher at baseline and at week three, and they 95 
were asked to consume the drink in their homes daily. Cocoa was consumed after an overnight fast at 96 
the same time each morning.  After the consumption of the drink, they were instructed to wait 30 97 
minutes before consuming any other food or beverage and/ or take their medication. Participants were 98 
instructed to take their medication and to follow their usual diet for the rest of the day.  The cocoa 99 
drinks (intervention and control) were designed to differ only in flavonoid content (low versus high 100 
flavonoid; supplementary file 2). Cocoa powder was provided to participants in air tight individual 101 
sachets. They were asked to add the sachet content to a mug and to add heated rice milk prior to 102 
consuming the drink. Instructions on preparation were provided to ensure all participants followed the 103 
same protocol. Unused cocoa powder was collected by the researcher at the next assessment. 104 
 105 
Outcomes 106 
The primary aim was to assess feasibility of the dietary intervention in terms of recruitment rate and 107 
the process of randomisation, adherence to the protocol and loss to follow up, safety and process. We 108 
documented adverse events (AEs). Duration of participation and dropout from the intervention were 109 
also recorded. Appropriateness of data collection methods was determined through completion of 110 
questionnaires and missing data, and through the process evaluation, and estimates of effect {effect 111 
sizes (ES) and confidence intervals (CI)} were calculated for the measures and demographics were 112 
collected at baseline. 113 
 114 
Fatigue and fatigability  115 
Throughout the six-week intervention participants were asked to rate their level of fatigue on a 116 
numerical rating scale (NRS) through daily ‘fatigue texts’ sent at 10:00, 15:00 and 20:00 every day, 117 
rating their fatigue between 1-10 (10 worst). They replied to the text message of ‘on a scale from 1-118 
10, with 1 being no fatigue and 10 being the worst fatigue you have experienced, how fatigued are 119 
you at the current time?’.  They did this at 10 am, 3 pm and 8 pm every day for six weeks. Fatigability 120 
was measured at baseline and week 6 using the six minute walk test (6MWT) [18]. Participants were 121 
asked to walk at their normal, comfortable walking pace back and forth on a measured 16-metre track 122 
in a University corridor. Distance walked was measured. At baseline, week 3 and 6 the levels of 123 
subjective fatigue experienced over the past seven days were measured using the Neuro-QOL short 124 
form questionnaire [19]. The Adult Memory and Information Processing Battery (AMIBP) [20] was 125 
used to measure cognitive fatigue. The AMIPB required the second highest number in each row to be 126 
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circled, with 15 rows of five double digit numbers. Participants had two minutes and their attempts 127 
were timed, with incorrect answers being noted. 128 
 129 
Questionnaires administered at baseline, week 3 and 6 were: the Physical Activity Scale for the 130 
Elderly (PASE) [21], EQ5D-5L [22], Preference-Based Multiple Sclerosis Index (PBMSI) [23] and 131 
the Hospital Anxiety and Depression Scale (HADS) [24]. Demographic information was collected. A 132 
previously published protocol paper gives detail about each measure [25]. Activity was monitored 133 
with seven-day wrist worn accelerometers (Axivities ®) prior to, and over two separate weeks of the 134 
trial (week 2-3 and 5-6).  135 
 136 
Blood markers of inflammation were measured including: TNF-alpha, reduced glutathione, a marker 137 
of antioxidant status and lipid peroxidation. 138 
 139 
Detailed description of measures can be found in supplementary file 1. 140 
 141 
Process evaluation 142 
Upon exiting the study at week 6, each participant was interviewed about the intervention process, 143 
ease of adherence, tolerance and acceptability of the flavonoid drink and the collection of outcome 144 
measures.  Participants were asked their opinion on the importance of the research question proposed 145 
to inform future trials. The thirteen topics used included difficulties with intervention delivery, 146 
scheduling of assessments and outcome measure acceptability and suggestions on how to improve the 147 
intervention process. A proportion of the data (20%) was coded by two different team members to 148 
check on reliability of the coding scheme. Transcripts of interviews were examined to identify themes 149 
and categories. Codes were applied to these broad themes, which were then broken down further into 150 
sub-codes. Agreement on concepts and coding by blinded assessors were sought between two 151 
members of the research team to ensure reliability.  152 
 153 
Analysis 154 
Feasibility was analysed through evaluation of eligibility, recruitment and retention [26]. 155 
Completeness of outcome measures was reported and 80% was set as a criterion for success. 156 
Retention was measured by the proportion of participants who were lost to follow-up. Successful 157 
adherence to the intervention was defined as at least 75% of the participants having completed cocoa 158 
consumption. Further aspects of adherence were measured by the percentage of fatigue texts 159 
completed by participants. 160 
Primary analysis followed the intention to treat principal utilised the complete case data set. 161 
Results were presented using point estimates and 95% confidence intervals. For the fatigue texts the 162 
fatigue NRS was calculated as the area under the curve (AUC) for each group, ignoring area beneath 163 
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the baseline, and was calculated geometrically [27]. Data was transformed to improve model fit, or 164 
different regression approaches were used (e.g. Negative Binomial, or Poisson regression). The results 165 
for the 6MWT are reported as mean ± SD and for the comparison of baseline and post-intervention as 166 
mean difference ± standard error [(SE); 95% (CI)]. A Linear Mixed Model (LMM) was used to 167 
differences between groups throughout all time points. Alternatively and wherever the variables were 168 
categorical, such as the EQ5D-5L sub categories, a generalized estimating equation (GEE) with 169 
appropriate distributions (e.g. Negative Binomial) method was implemented. Both methods used 170 
SAS/STAT 14.3. Fatigue and fatigability measures including the Neuro-QoL short form fatigue, the 171 
6MWT and the AMIPB were further analysed to determine difference between responders and non-172 
responders and relative risk scores then calculated.  Responders on the NeuroQol, for both the control 173 
and intervention groups, were classified as those who had a clinically meaningful change of 10 points 174 
out of 100 (with the questionnaire total score converted from an original total of 40 between baseline 175 
and week 6. Responders on the 6MWT were classified as those who had a minimally important 176 
change (MIC) in covered distance of 21.6m [27] between baseline and week 6. 177 
Data over three time points for activity data was analysed using a Freidman’s test and 178 
between group effects were calculated using a Mann-Witney test. Process evaluation included 179 
frequencies for adhering to the intervention, session content and progression which was analysed 180 
descriptively with confidence intervals and regression where possible. A standard content analysis 181 
techniques were employed. 182 
  183 
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Results 184 
 185 
 186 
 187 
Between May 2016 and August 2017, 40 pwMS were recruited from four neurology clinics including: 188 
Oxford University Hospitals NHS Trust (John Radcliffe Hospital site), Milton Keynes hospital, Royal 189 
Berkshire hospital or Buckingham hospital or through advertisements and online media (MS Society 190 
webpage and MS Trust Facebook page).  191 
 192 
Figure 1 shows participant flow. It was not possible to determine the total number of people screened.  193 
 194 
 195 
 196 
Feasibility 197 
Fifty-three people showed an initial interest in the trial, but decided not to take part due to: not having 198 
enough time to take part in the trial, did not like chocolate, or were unable to take part in nutrition 199 
trials due to being on weight loss programs or having gastric surgery. All but one person consumed 200 
the cocoa with rice milk (one consumed almond milk). One person discontinued the control 201 
intervention but was not lost to follow up and one person consented to be on the trial but decided not 202 
to consume the cocoa from the start of the intervention. Adherence to intervention overall was 100% 203 
(19/19) for the intervention group and 90% (19/21) for the control group. Missing data from NRS was 204 
less than 20% of total responses, but reporting did drop in week 6. Blood measures were only 205 
achieved in 20 participants (after a maximum of three attempts).  Overall missing data for secondary 206 
measures was less than 20%. There were seven AEs during the trial, caused by worsening fatigue, 207 
feelings of nausea, or a general feeling of being unwell. AEs were considered unlikely to be related 208 
(five), possibly related but expected/ resolved (one) and not related to the intervention (one). Four 209 
AEs were associated with the control cocoa and three with the high flavonoid cocoa. There were no 210 
incidences of un-blinding of the researcher nor participant. Five out of 40 people were seen at home at 211 
week 3.  212 
Demographic and clinical data are shown in Table 1.  There were no significant differences 213 
for demographics between the groups at baseline (p>0.05).  214 
 215 
 216 
 217 
 218 
 219 
 220 
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Table 1. Demographic data 221 
 Demographic information at baseline for both groups 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
Values are means ± standard deviations, or total number of people in () considering the percentage of 253 
the total sample population. FSS and Barthel Index totals are reported as medians ± ranges. An 254 
independent t-test was used to compare means for age, BMI, PASE. A Mann-Witney U test was used 255 
to compare medians for FSS and BI for non-parametric measures to determine differences between 256 
 Intervention (n = 19) Control (n = 21) 
   
Age (years)  
 
41 ± 11 46 ± 8 
Women  14 (74%) 16 (76%) 
   
   
BMI (kg/m2)  26 ± 7 25 ± 6 
   
Treatment naïve 7/19(37%) 6/21(29%) 
   
   
Medications 
 
  
  Anti-depressants/anxiolytic 
  
  Anti-convalescents/anti-  
  spastics 
  
  Sedating analgesic 
  
  Other sedating 
  
  Other (excluding DMTs) 
6 
 
3 
 
 
0 
 
2 
 
25 
6 
 
6 
 
 
1 
 
7 
 
24 
   
Smokers  
 
0(0%) 2(10%) 
Uses assistive device 
 
2(11%) 6(29%) 
Report food allergy 
 
2(11%) 2(10%) 
Reported food intolerance 
 
6(32%) 5(24%) 
Reported taking special diet 
 
4(21%) 2(10%) 
Fatigue Severity Scale (FSS) 
Total  
 
5 ± 2 5 ± 3 
Barthel Index (BI) Total 
 
20 ± 2 19 ± 8 
Physical Activity for the 
Elderly (PASE) Total  
90 ± 32 102 ± 31 
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the intervention groups. A chi-squared test was used to compare means for nominal data. There were 257 
no significant differences between groups for any baseline measures (p>0.05). 258 
Outcome measures  259 
 260 
Between group effect sizes were considered from all three assessments points.  Efficacy potential of 261 
fatigue and feasibility was determined. A breakdown of the outcome measures is shown in Table 2. 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
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Table 2. Results for outcome measures at baseline, week 3 and week 6 of the intervention.a 278 
 279 
a. Vales are means ± SE for normally distributed values and medians ± ranges (1st to 3rd quartile) for categorical data.  280 
b. Effect sizes and CI’s are Cohen’s d, based on non-central t distributions of least squares means differences for continuous 281 
variables, using SAS 9.4 and Cliff’s delta, for categorical variables, using R 3.5. 282 
c. Relative risks were calculated for measure of fatigue and fatigability for responders versus non responders.   283 
 Control     Intervention     
 Baseline 
(n=21) 
3 weeks 6 weeks  Baseline 
(n=20) 
3 weeks 6 weeks Relative 
risk c 
Effect 
sizes with 
95% CI b 
           
Fatigue 
Neuro-QoL 
 
25.86 ± 
1.27 
 
22.55 ± 
1.18 
 
22.95 ± 
1.51 
  
27.63 ± 0.88 
 
24.21 ± 
1.21 
 
22.95 ± 
1.17 
 
1.45 
 
0.04 (-
0.40-0.48) 
Fatigability  
AMIPB 
Incorrect 
 
 
1 ± 2 
 
 
1 ± 1 
 
 
1 ± 2 
  
 
0  ± 1 
 
 
0  ± 1 
 
 
0  ± 1 
 
 
 
 
 
-0.13 (-
0.34-0.09) 
Time 53.83  ± 
3.83 
55.80  ± 
5.00 
52.43 ± 
3.44 
 58.85  ± 4.01 57.66  ± 
4.07 
58.67 ± 
4.74 
 0.11 (-
0.34-0.55) 
6 minute walk 344  ± 
17.67 
n/a 354.5  ±  
19.29 
 360.9  ±  
13.15 
n/a 394.6 ± 
18.11 
1.80 0.45 (0.18 
- 1.07) 
Numerical 
rating scale 
fatigue 
n/a 35 + 12 34 + 16  n/a 33 + 18 31 + 18   
QoL 
EQ5D-5L 
Mobility 
 
 
2 ± 3 
 
 
2  ± 3 
 
 
1.5  ± 3 
  
 
1 ± 2 
 
 
1 ± 2 
 
 
1 ± 2 
  
 
-0.02 (-
0.26-0.22) 
Self-care 1  ± 2 1  ± 2 1  ± 2  1 ± 1 1 ± 1 1 ±  1  -0.30 (-
0.43—
0.16) 
Usual activities 2  ± 3 2  ± 2 2  ± 3  2  ± 2 2  ± 2 2  ± 2  -0.12 (-
0.33-0.11) 
Pain/ 
discomfort 
2  ± 3 2  ± 3  2 ± 3  2  ± 3 2  ± 2 2  ± 3  -0.25 (-
0.45—
0.02) 
Anxiety/ 
depression 
1  ± 2 1  ± 2 1 ±  2  2 ± 2 2  ± 2 2 ± 2  0.15 (-
0.07-0.36) 
Health today 
VAS 
67.71 ± 
3.30 
68.50  ± 
3.98 
74.15 ± 
3.56 
 71.58  ± 3.48 71.95  ± 
3.25 
72.79  ± 
3.30 
 0.24 (-
0.21-0.69) 
HADS 
Depression 
 
5  ± 8 
 
4  ± 7 
 
4.5  ± 9 
  
4  ± 5 
 
5  ± 7 
 
5  ± 7 
  
0.09 (-
0.15-0.33) 
Anxiety 7.62± 
0.74 
7.25± 
0.70 
6.65± 
0.80 
 7.32± 0.83 7.21± 
0.83 
6.63± 
0.82 
 0.14 (-
0.31-0.58) 
PBMSI 
Walking 
 
2  ± 2 
 
2  ± 2 
 
1.5 ± 2 
  
1 ± 2 
 
1 ± 2 
 
1.5 ± 2 
  
-0.15 (-
0.35-0.07) 
Fatigue 2 ± 2 2  ± 2 2 ± 2  2 ± 2 2  ± 2 2 ± 2  -0.12 (-
0.29-0.06) 
Mood 1 ± 2 1  ± 2 1 ± 2  1 ± 2 1 ± 2 1 ± 2  -0.10 (-
0.30-0.11) 
Concentration 2 ± 3 2 ± 2 2  ± 2  2 ± 2 2 ± 2 2 ± 2  0.05 (-
0.15-0.26) 
Roles/ 
responsibility 
1 ± 2  1 ± 2 1 ± 2  1 ± 2 1 ± 1 1 ± 2  -0.06 (-
0.25-0.14) 
Mechanism 
Plasma 
Lipid 
peroxidation 
 
 
0.66  ± 
0.01 
 
 
0.68  ± 
0.01 
 
 
0.67  ± 
0.01 
  
 
0.69  ± 0.01 
 
 
0.69  ±  
0.01 
 
 
0.70  ± 
0.02 
  
 
0.50 (0-
0.99) 
TNF-alpha 0.12  ±  
0.01 
0.12  ±  
0.01 
0.10 ± 
0.01 
 0.13  ± 0.01 0.11  ± 
0.01 
0.11 ± 
0.01 
 0.01 (-
0.22-0.23) 
Glutathione 0.0043 ± 
0.0047 
0.0045 ± 
0.0031 
0.0035 ± 
0.0030 
 0.0034 ± 
0.0051 
0.0035 ± 
0.0041 
0.0060 ± 
0.0040 
 0.07 (-
0.55-0.69) 
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Physical activity levels over the intervention period can be seen in Table 3. 284 
 285 
Table 3. Physical activity levels (reported in minutes per day on average) using an accelerometer 286 
watch prior to the intervention, between 9 to 16 days (3 weeks) into the intervention and between 35 287 
to 42 days(6 weeks) at the end of the intervention, broken down into sedentary light moderate and 288 
vigorous classification. 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
Vales are means ± SE. Total activity for each participant was broken down into sedentary, light, moderate and 305 
vigorous and average for all participants in each group, over each 7-day time period.  306 
 307 
 308 
 309 
Fatigue and fatigability  310 
Fatigue was further analysed to determine difference between responders and non-responders. There 311 
was no difference in means between groups (p>0.05) yet the Relative Risk (RR) for those who 312 
responded and therefore had improved fatigue in the intervention group (11 out of 19 responders) to 313 
the control group (8 out of 20 responders) was 1.45. The AMIPB was assessed in a similar way with a 314 
change in 1 SD of an improvement in 11.5 seconds considered clinically meaningful. Based on these 315 
criteria only one person improved in the intervention group and no one in the control group and 316 
therefore a RR was not calculated.  317 
There was a medium effect size for distance walked in six minutes (0.45 {CI 0.18-1.07}) 318 
between the groups with the intervention showing a larger increase in the metres walked in 6 minutes 319 
after the intervention (Table 2). The RR for responders in the intervention group compared to control 320 
was 1.80 in favour of the intervention group. 321 
 322 
Process evaluation  323 
Both groups had similar positive experiences about the scheduling of the assessments. 13/19 in the 324 
intervention vs 18/20 people in the control indicated no impact of the measurement instruments used 325 
on weekly routine over the six weeks. Similar numbers in both groups identified that the outcome 326 
measures were acceptable. Randomisation: Most comments from both groups indicated acceptance 327 
towards the process of randomisation. Taste: Similar numbers (8/19 intervention vs 9/20 control) 328 
reported positive comments about the taste of the cocoa. Procedures and routine of preparing the 329 
  Baseline 
control 
3 weeks 6 weeks  Baseline 
interventi
on 
3 weeks 6 weeks 
Activity 
Sedentary  
 1052.97 
± 23.78 
1031.17 
±28.07 
1049.98±1
9.12 
 1049.20 
± 29.97 
1090.68±
32.06 
1061.76 
±22.11 
Light  302.48 ± 
15.15 
304.68 
±17.78 
305.16 
±14.22 
 317.59 
±24.28 
293.98 ± 
23.53 
311.70±
18.44 
Moderate  83.44 
±13.67 
101.76 ± 
14.29 
82.59 
±10.12 
 71.78±9.
63 
76.04±9.
64 
82.04±9
.91 
Vigorous   1.67 
±0.69 
1.65 
±0.82 
1.99 ±1.19  1.98 
±0.93 
2.74 
±1.05 
1.55±0.
49 
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drink: A few individuals in both groups identified that it was inconvenient to wait for food after drink 330 
consumption (4/19 intervention vs 3/20 control), and that the process did not always fit in with their 331 
lifestyle e.g., traveling. Other individuals (15/19 intervention vs 17/20 control) identified that they 332 
worked it into a routine. Continuation of consuming the drink: half of both groups (9/19 intervention 333 
vs 11/20 control) said they would continue the drink if offered. A further four people in both groups 334 
said they would continue if it was beneficial or if they could implement their own routine.  335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
  345 
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Discussion 346 
PwMS engaged with the dietary intervention, with fatigue and fatigability measures responding more 347 
in the intervention group with effect sizes calculated. The current study was shown to be feasible and 348 
well received by pwMS, with high adherence to the intervention and excellent data completion. Our 349 
study establishes that the use of dietary interventions is feasible and may offer possible long-term 350 
benefits to support fatigue management, by improving fatigue and walking endurance. We further 351 
propose that considering the possible anti-inflammatory mechanism, flavonoids may be used as an 352 
adjunctive approach alongside other therapeutic interventions and suggest the possible benefit of such 353 
combined approaches for fatigue management. However further full powered trials would need to be 354 
performed. 355 
The time post diagnosis was extended from five to ten years in order to recruit to target (n = 356 
40). Adherence (>75%), retention and amount of missing data (<80%) were within the acceptable 357 
ranges. Most missing data was from the NRS texts over the six weeks which is not surprising as this 358 
was the most time-consuming part of the assessment. Completion was still above 80% of total with 359 
the first five weeks, with week six showing the most missing data. Mild AEs have previously been 360 
reported when consuming high flavonoid cocoa including nausea and vomiting, gastrointestinal 361 
disturbances and headaches [28]. The AEs reported in the current trial did not cause any safety 362 
concerns and were similar between groups. 363 
This is the first study to suggest the potential for fatigability being improved through a 364 
6MWT after six weeks of a flavonoid intervention, with a moderate effect size. In the current study 365 
the intervention showed a MIC over time with 33.7m (SE: 8.4) in contrast to the control group 10.2m 366 
(SE: 9.6).  Fatigue correlates with a decrease of physical endurance [29] and walking speed [30] and 367 
therefore a treatment targeting fatigue could also improve walking performance. Flavonoid have been 368 
found to increase cerebral blood flow by inducing widespread stimulation of brain perfusion, and this 369 
could also influence mood, cognitive performance, fatigue perception and ability to perform specific 370 
movement tasks [31]. When considering other symptoms, pain was shown to improve in the flavonoid 371 
group over the six weeks as measured by the EQ5D-5L with a moderate effect size. The antioxidant 372 
properties of flavonoids are thought to lesson neuropathic pain by alleviating oxidative stress and thus 373 
reducing neuron damage caused by lipid peroxidation. [32]. We did not measure objective measures 374 
of pain in this trial and therefore further research is warranted to explore the pain improvement. 375 
Indeed previous research has pointed towards higher motivation in physical activity in pwMS when 376 
symptoms such as pain were improved [33]. This may also allow pwMS to become more active and 377 
mobile, as noted by the improvements on the 6MWT.  378 
The process evaluation revealed that overall the trial was well accepted, with the timing of 379 
assessments and the outcome measures being convenient and low burden, respectively and the 380 
participants in both groups found the taste of the cocoa enjoyable, or noted it as neither tasty nor 381 
unacceptable. In both groups the blinding and randomisation process were accepted, and a majority of 382 
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pwMS in both groups declared their willingness to continue consuming the cocoa long term, 383 
especially if benefits to fatigue were found. However findings around the preparation of the drink and/ 384 
or scheduling the timing of drink consumption into ones routine are factors to consider for future 385 
trials.  386 
 387 
Limitations  388 
As a feasibility study a powered investigation using a sample size of 80 is now needed. For blood 389 
measures, the lack of ability of the phlebotomist to collect blood from several of the participants led to 390 
missing data. From the data collected, there were small effect sizes in blood indicators, apart from 391 
lipid peroxidation which showed a moderate effect size and therefore this area needs further 392 
investigation. The NRS fatigue data was analysed as a total whole change over the six weeks, and 393 
therefore more sensitive analysis may have discovered changes within the six weeks.  Fatigue may be 394 
both physical and cognitive and coexists with and is impacted by a number of factors including 395 
anxiety and depression. This study measured a number of these factors including: motor (6MWT) and 396 
cognitive (AMIPB) fatigue, and anxiety and depression (HADS) which could be further investigated 397 
in a study powered for this.  In this pilot we set out to reduce variability from these factors where 398 
possible, for example we excluded individuals with a clinical diagnosis or receiving treatment for 399 
depression (such as individuals on antidepressants)    400 
 401 
It should be considered that, while we used a wide range of recruitment methods reducing the risk of 402 
recruitment bias, participants were recruited from afﬂuent areas of the UK. Acknowledging this 403 
limitation, we nevertheless propose the responses in outcome measures are largely generalizable to 404 
relatively healthy pwMS. 405 
 406 
Conclusion 407 
 408 
The use of dietary approaches to reduce fatigue and associated factors in pwMS may be an easy, safe 409 
and cost effect way to impact on quality of life and independence, allowing people to feel more in 410 
control of their condition. A full evaluation including wider geography, longer follow up and cost 411 
effectiveness is now indicated. This technology has the potential to be implemented in the UK and 412 
worldwide, and alongside other rehabilitation including exercise, DMTs and physiotherapy. 413 
 414 
Figure 1 Flow of recruitment legend: The screening and enrolment process for a 6 week randomised 415 
double-blind placebo-controlled feasibility trial in people with Multiple Sclerosis. A total of 40 people 416 
were included in the final analysis, and reasons for not receiving the allocated intervention (cocoa 417 
drink) and discontinuation are presented.  418 
 419 
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Figure 1 Flow of recruitment  
 
Assessed for eligibility (n=229) 
Not eligible and Excluded (n=189) 
   Not meeting inclusion criteria (n=38) 
   Declined to participate (n=53) 
   No response (n=98) 
Analysed  (n=19) 
 Excluded from analysis (n=0) 
Week 3; Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to six week intervention (n=19) 
 Received allocated intervention (n=19) 
 Did not receive allocated intervention (n=0) 
Week 3; Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
 
 
Allocated to six week control (n=21) 
 Received allocated intervention (n=20) 
 Did not receive allocated intervention (did not 
want to consume sugar) (n=1) 
Analysed  (n=21) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=40) 
Enrollment 
Week 6; Lost to follow-up (n=0) 
Discontinued intervention (feeling unwell) (n=1) 
 
Week 6; Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
